Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Raw Materials (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Raw Materials data on record, last reported at $2.5 million in Q3 2025.

  • For Q3 2025, Raw Materials fell 25.82% year-over-year to $2.5 million; the TTM value through Sep 2025 reached $2.5 million, down 25.82%, while the annual FY2024 figure was $3.1 million, 14.95% down from the prior year.
  • Raw Materials reached $2.5 million in Q3 2025 per TNXP's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Raw Materials topped out at $3.6 million in Q4 2023 and bottomed at $2.3 million in Q2 2025.
  • Average Raw Materials over 3 years is $2.9 million, with a median of $2.9 million recorded in 2024.
  • Peak YoY movement for Raw Materials: decreased 14.95% in 2024, then dropped 25.82% in 2025.
  • A 3-year view of Raw Materials shows it stood at $3.6 million in 2023, then dropped by 14.95% to $3.1 million in 2024, then dropped by 19.18% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $2.5 million in Q3 2025, $2.3 million in Q2 2025, and $2.7 million in Q1 2025.